Literature DB >> 10904248

Molecular strategies for overcoming antibiotic resistance in bacteria.

Y T Tan1, D J Tillett, I A McKay.   

Abstract

Overuse of antibiotics in humans and livestock has led to the rapid evolution of bacteria that are resistant to multiple drugs such that even vancomycin, the drug of last resort, is no longer effective against some strains. Apart from the discovery and exploitation of the natural peptide antimicrobial agents that form part of the innate immune systems of plants and animals, there have been few new antibiotics developed in recent years. Here we review strategies designed to exploit recent advances in molecular biology, including recombinant DNA technology, molecular modelling and genomics to develop new antibacterial agents that overcome antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10904248     DOI: 10.1016/s1357-4310(00)01739-1

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  11 in total

1.  The 79,370-bp conjugative plasmid pB4 consists of an IncP-1beta backbone loaded with a chromate resistance transposon, the strA-strB streptomycin resistance gene pair, the oxacillinase gene bla(NPS-1), and a tripartite antibiotic efflux system of the resistance-nodulation-division family.

Authors:  A Tauch; A Schlüter; N Bischoff; A Goesmann; F Meyer; A Pühler
Journal:  Mol Genet Genomics       Date:  2003-01-10       Impact factor: 3.291

Review 2.  Towards rational treatment of bacterial infections during extended space travel.

Authors:  Peter W Taylor; Andrei P Sommer
Journal:  Int J Antimicrob Agents       Date:  2005-09       Impact factor: 5.283

3.  Multivalent dendritic molecules as broad spectrum bacteria agglutination agents.

Authors:  Shuzhang Xiao; Lica Abu-Esba; Serhan Turkyilmaz; Alexander G White; Bradley D Smith
Journal:  Theranostics       Date:  2013-08-10       Impact factor: 11.556

4.  Identifying co-targets to fight drug resistance based on a random walk model.

Authors:  Liang-Chun Chen; Hsiang-Yuan Yeh; Cheng-Yu Yeh; Carlos Roberto Arias; Von-Wun Soo
Journal:  BMC Syst Biol       Date:  2012-01-19

5.  Maximum flow approach to prioritize potential drug targets of Mycobacterium tuberculosis H37Rv from protein-protein interaction network.

Authors:  Tilahun Melak; Sunita Gakkhar
Journal:  Clin Transl Med       Date:  2015-06-05

Review 6.  The use of platensimycin and platencin to fight antibiotic resistance.

Authors:  Adil M Allahverdiyev; Melahat Bagirova; Emrah Sefik Abamor; Sezen Canim Ates; Rabia Cakir Koc; Meral Miraloglu; Serhat Elcicek; Serkan Yaman; Gokce Unal
Journal:  Infect Drug Resist       Date:  2013-09-18       Impact factor: 4.003

7.  Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype.

Authors:  Naseem Mushtaq; Maria B Redpath; J Paul Luzio; Peter W Taylor
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  A Strong Synergy Between the Thiopeptide Bacteriocin Micrococcin P1 and Rifampicin Against MRSA in a Murine Skin Infection Model.

Authors:  Kirill V Ovchinnikov; Christian Kranjec; Amar Telke; Morten Kjos; Tage Thorstensen; Siegfried Scherer; Harald Carlsen; Dzung B Diep
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

9.  Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance.

Authors:  Karthik Raman; Nagasuma Chandra
Journal:  BMC Microbiol       Date:  2008-12-23       Impact factor: 3.605

10.  Microbial Competition of Rhodotorula mucilaginosa UANL-001L and E. coli increase biosynthesis of Non-Toxic Exopolysaccharide with Applications as a Wide-Spectrum Antimicrobial.

Authors:  Augusto Vazquez-Rodriguez; Ximena G Vasto-Anzaldo; Daniel Barboza Perez; Eduardo Vázquez-Garza; Héctor Chapoy-Villanueva; Gerardo García-Rivas; Javier A Garza-Cervantes; Jéssica J Gómez-Lugo; Alma Elizabeth Gomez-Loredo; Maria Teresa Garza Gonzalez; Xristo Zarate; Jose Ruben Morones-Ramirez
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.